Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice

Medicine and Dentistry

• Glucagon Like Peptide 2 100%
• Glycemic Control 100%
• Glucagon Like Peptide 1 100%
• Gut 100%
• Body Weight 80%
• Monotherapy 60%
• Chronic Drug Administration 60%
• Maturity Onset Diabetes of the Young 40%
• Stomach Emptying 40%
• Food Intake 40%
• Glucose Tolerance 40%
• Short Bowel Syndrome 40%
• Disease 20%
• Diabetes Mellitus 20%
• Medicine 20%
• Morphometrics 20%
• Glucose Homeostasis 20%
• Liraglutide 20%
• Peptide Hormone 20%
• Small Intestine 20%
• Pharmacokinetics 20%
• Peptide Synthesis 20%
• Teduglutide 20%
• Mucosal Surface 20%
• Gastrointestinal Polypeptide 20%

Keyphrases

• Glycemic Control 100%
• Glucagon-like 100%
• Co-agonist 100%
• Monotherapy 30%
• Leaner Mouse 30%
• Type 2 Diabetes Mellitus (T2DM) 20%
• Gastric Emptying 20%
• Glucose Tolerance 20%
• Short Bowel Syndrome 20%
• Short-acting 20%
• Subchronic Administration 20%
• Food Intake 10%
• Obesity 10%
• Glucose Homeostasis 10%
• Dose Effect 10%
• Disease Treatment 10%
• Diabetic 10%
• Liraglutide 10%
• Type 2 Diabetes Prevention 10%
• Small Intestine 10%
• Gastrointestinal Hormones 10%
• Pharmacokinetic Properties 10%
• Chronic Administration 10%
• Db Mouse 10%
• Diabetic Mice 10%
• Solid-phase Peptide Synthesis 10%
• Teduglutide 10%
• Mucosal Surfaces 10%
• Agonistic 10%
• Reduced Food Intake 10%
• Persistent Effects 10%
• Long-term Glycaemic Control 10%
• Lean in 10%
• Gut Morphometry 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Mouse 100%
• Glucagon Like Peptide 2 100%
• Glucagon-Like Peptide-1 100%
• Monotherapy 60%
• Leaner Mutant Mouse 60%
• Non Insulin Dependent Diabetes Mellitus 40%
• Short Bowel Syndrome 40%
• Disease 20%
• Pharmacokinetics 20%
• Diabetes Mellitus 20%
• Liraglutide 20%
• Peptide Hormone 20%
• Teduglutide 20%
• Db/Db Mouse 20%
• Gastrointestinal Polypeptide 20%